Process validation and preclinical development of a new PET cerebral blood flow tracer [11C]MMP for initial clinical trials

• Autori principali: Jun Toyohara (Autore), Tetsuro Tago (Autore), Muneyuki Sakata (Autore)
• Natura: Libro
• Pubblicazione: SpringerOpen, 2024-07-01T00:00:00Z.
• Soggetti: article
• Accesso online: Connect to this object online.

Abstract Background 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) is commonly used for diagnosis of dementia because brain glucose metabolism reflects neuronal activity. However, as [18F]FDG is an analogue of glucose, accumulation of tracer in the brain is affected by plasma glucose levels. In contrast...